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Abstract 
 
Background: The objective of this study was to investigate the fatty acids profiling in diabetic rats induced by sterptozocine (STZ) 
and their response to administration of lutein and carnitine.  
Materials and methods: Ninety male albino rats were divided into 6 groups as follows: Normal control. The remaining rats were 
injected i.p a single dose of STZ (65 mg /kg bw) for induction of diabetes. Diabetic rats were grouped as: GP II: (Untreated): GP III: 
Rats were given orally with L-lutein (100 mg/kg bw).GP IV: Rats were given carnitine (30 µg/kg) i.p. GP V: Rats were given 
carnitine and lutein GP VI were given metformin (100mg/kg bw/d) for 6 weeks.  
Results: Treatment of diabetic rats with lutein, L-carnitine, combined decreased the levels of glucose, HA1C compared with 
untreated diabetic (p<0.001). Administration of L-lutein, carnitine, combined to normal rats significantly decreased the levels of  
myristic, palmitice, palmitoleic, stearic, linoleic, α-linolenic, arachidic and eicosadienoic when compared with control normal rats 
(p<0.001).  
Conclusion: Abnormalities of fatty acids composition was observed in diabetic rats. Combination treatment with lutein and carnitine 
could ameliorate deleterious effect induced by STZ and attenuate the changed fatty acid composition 
 
Key words: Fatty acids profiling- lutein-carnitine-rats 
 
Introduction 
 
Diabetic is considered the most medical problem the world over. Most research focuses on lowering the prevalence of 
disease by early predication or minimizes its complications that increase morbidity and mortality [Ridderstråle and Groop, 2009].  
Metabolomics is a new research trend deployed to discover various metabolites in different cases (normal and diseases) in biological 
fluids can be used as diagnostic or prognostic biomarkers or therapeutic protocol [Muoio and Newgard, 2008]. This allows for 
accurate and rapid identification of that disease. Metabolomic strategies present several practical advantages, including cost 
effectiveness per sample, high throughput and fully automated [Castle et al.,2006]. Metabolomics profiling might be an early 
diagnostic and prognostic biomarkers for diabetic and we will see the basis of biomarker for the disease and detect were most 
deregulated that might be the basis of biomarker for the disease therapies that intend to correct metabolic deregulation [German  
etal.,2005]. Life styles and feeding could affect the resulting metablomic deregulation; hence affects the nature and aggressiveness of 
the disease by doing this research we will show which differences in the metablomic profiling [Matthews etal.,1985]. However, we 
do not know whether the biomarkers found from these metabolomics research could also be applied on Saudi patients due to 
differences in life styles and feeding .This could be said to have justified obtaining serum as a tool for early detection of diabetes. 
But we will focus on the markers that has been shown to be most deregulated in diabetic rats [Hollywood  et al., 2006]. L-Carnitine 
is an important fatty acyl carrier from cytosol to mitochondrial matrix for β oxidation. It obtained from diet (animals sources) or be 
synthesized from lysine and methionine. Deficiency of carnitine resulted in decrease oxidation of fatty acids and decreased energy 
supplied to vital organs as heart, nervous system and skeletal muscles [Lindon et al., 2007].   
Lutein is a xanthophyll member of carotenoids, which is synthesized in green leaf plants. It was recorded as safe when 
supplemented to foodstuff [Han and Gross, 2003]. Lutein is absorbed via lipoprotein in the intestinal tract. Tissue content of lutein is 
related to dietary intake. After intake, lutein concentration is approximately 0.2 μM in circulation to different tissues and play 
important role in maintenance of tissue homeostasis [Watson, 2006]. Reactive oxygen species (ROS) was considered the most 
common free radical in the cell. It is generated as byproducts in metabolism of drugs. The accumulation of these radicals has been 
reported as a mechanism for apoptosis. Luteins plays an effective role in the removal of free radicals [Lin et al., 2011]. 
  The rational behind this study is to evaluate the importance of lutein and carnitine in enhancing the metabolism and 
management of diabetic complications. In this study we will focus on the changes in free fatty acids metabolites that have been 
secondarily affected and could serve as a biomarker for the disease or substantially for those which are behind but associated with 
the disease. This will enhance the understanding the pathogenesis of the disease from a metabolomics. The main objective of this 
study is to identify free fatty acids metabolites in diabetic rats and their response to administration of lutein and carnitine. This will 
help to know the biological role of lutein and L-carnitine in modulation the metabolism in diabetes and consequently the 
complications and severity of the diseases.  
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Materials and Methods 
 Animals 
 
Ninety male albino rats weighting between 200±20 g were included in this study. Rats were divided into 6 groups (each 15 
rats) as follows: Group I: Control group which was received a single dose of 0.1 mol/l citrate buffer only. The remaining rats were 
injected with a single dose of streptozocine (STZ) (65 mg /kg b.w) i.p for induction of diabetes. These animals developed diabetes 
within three days. Blood sugar more than 250 mg/dl was considered diabetic. Diabetic rats were divided into five groups as follows: 
GP II: (Untreated diabetic): GP III: Rats were given orally with L-lutein (100 mg/kg bw).GP IV: Rats were given with L-carnitine 
(30 g/kg b w) ip. GP V: Rats were given L-carnitine and lutein. GP IV: rats were given metamorfin (10 mg/kg bw) daily. At the 
end of the experiments (6 weeks). Blood was collected directly from all groups. Serum was used for the determination of glucose, 
glycated hemoglobin, urea, creatinine and nitric oxide, malondilaldhyde [Shearer etal.,2008], total antioxidant activity. Superoxide 
dismutase, interleukin-6, tumor necrosis factor (TNF-α) by using ELISA kit from BIORAD, ENGLAND.            
 
 
Profiling of serum fatty acids  
 
Serum fatty acids were extracted with mixture of chloroform/methanol (2:1). Methyl ester of fatty acids (FAME) were 
prepared with by using 20% triflouroboron with methanol 110°C. Analyses of the ester were done by GC using from Agilent 
Company.  The GC was equipped with capillary column 60m, 0,25mm) and flame ionization detector at 260°C and injector at 
250°C.  The carrier gas used was Helium with flow rate at 43cm/sec. The retention times of standards fatty acids were used. For all 
fatty acids the mean value in percent was calculated [Rebouche and Chenard,1991].  
 
Statistical analysis 
 
The data were calculated as mean ± SD using SPSS, version 22. Any significant differences between different treated 
groups using ANOVA test.  
 
 
 
Results 
 
The body weight of the rats at the beginning of the study were similar in all groups. At the end of the experiment, 
diabetic animals presented a significant weight loss (p <0.001). The weights of the rats at the beginning of the study were 
similar in all groups. At the end of the experiment, diabetic animals presented a significant weight loss. Injection of rats with 
STZ resulted in a significant increase in blood glucose levels in the diabetic group compared with the control group (p 
<0.01), while treatment with lutein or carnitine or combined resulted in a significance decrease in blood glucose compared 
with the untreated diabetic animals (p <0.05, table 1). As a result, diabetes, HbA1c was significantly increased (p<0.05) in 
the diabetic untreated group. Treatment of animals with lutein or carnitine or combined improves the two parameters in a 
dose dependent manner (table 1). The HCA exert hypoglycemic action but less potent than insulin (p<0.05).  
 
 
Table 1: Body weight and blood glucose and glycated hemoglobin levels in all groups 
 Group 1 Group IIa Group IIb Group IIc Group IId 
Initial body weight( gm) 120.13±9.5 125.44±7 129.19±6 122±7.2 131.33±6.5 
Final body weight( gm) 199.5±8.2 150.8±7.2
a 167.3±16.5a,b 165.52±8.9a,b 210±12.3a,b 
Glucose ( mg/dL) 92.78±0.45 275.35±1.45
a 145.92±1.4a,b 137.71±1.23b 102.21±0.57a,b 
HbA1c( %) 5.54±0.41 8.42±0.34
a 6.8±0.54 b 6.8±0.38 b 5. 8±0.52 b 
 
 
The antioxidant activities like GSH reduced, catalase, SOD in retina of diabetic animals were significantly reduced as a 
result of STZ injection. Supplementation of lutein or L-carnitine or combined resulted in a significant elevation in GSH 
(p<0.05 for each) level and the activities of catalase and SOD (p<0.001, <0.01 and <0.05)) respectively (table 1). The 
elevation of the antioxidant enzymes was found to be dose dependent. The degree of lipid peroxidation in the retina was 
significantly elevated as a result of diabetes. Administration of the combined dose resulted in a dose dependent decrease of 
MDA levels, table 1.   
 Figures (1, 2) showed that, serum aldolase reductase and total antioxidant activities were significantly decreased in 
diabetic rats when compared with the controlled ones (p<0.01 and 0.001) respectively. Lutein or L-carnitine or combined 
showed an elevation in these activities with dose dependent. The enhancement in insulin injection is better than alone 
(p<0.05). 
 Figure 3 showed that, both TNFα and IL-1 play an important role in the pathogenesis of diabetic retinopathy. As a 
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result of STZ injection the retinal levels of TNFα and IL-1 were significantly elevated (p<0.001) for each indicating a 
considerable level of inflammation compared with the normal control rats. Administration of lutein or carnitine or combined 
results in a significant and a dose dependent reduction of these elevated levels (p<0.01). As a result of diabetes and enhanced 
formation of AGEs was marked and activated in the diabetic untreated group compared with the normal control group. HCA 
supplementation lutein or L-carnitine or combined resulted in a significant reduction of AGEs in a dose dependent manner as 
indicated in Figure3. HCA attenuated AGE production compared with insulin (p<0.001). 
 
 
Table 2: Serum malondialdhyde (MDA) level and reduced glutathione (GSH) levels, catalase, and superoxide dismutase (SOD) activity 
in retina of different groups (Mean +S.D)  
Groups Serum 
MDA 
µmol/mg protein 
GSH 
µg /mg 
protein 
Catalase 
U/mg protein 
SOD 
U/mg protein 
Group I  
Range 
Mean ±S.D. 
 
 
98-196 
66.7 + 28 
 
 
104 – 546 
284 +52 
 
992-2349 
1249 +140 
 
956 – 2623 
1545 +191 
Group II  
Range 
Mean±S.E. 
p* value 
 
190-261 
188 + 37 
N. S. 
 
68.7-221.5 
123.6 +19.3 
< 0.01 
 
109.5 – 642 
358 +65 
<0.001 
 
453-1342 
760+78 
<0.001 
Group III 
Range 
Mean ± S.E. 
p* value 
 
149 – 213 
142 + 32 
<0.001 
 
121 – 496 
259 +50 
<0.001 
 
706 – 2002 
843 +134 
<0.001 
 
876 -1987 
1021 +163 
<0.001 
Group IV  
Range 
Mean + S.E. 
p** value 
 
136-261 
133+ 25 
<0.001 
 
69.6- 213.9 
128 + 16.4 
p< 0.05 
 
456 -1632 
987 +56 
<0.001 
 
962-1316 
836+53 
<0.001 
Group V  
Range 
Mean + S.E. 
p** value 
 
156-261 
121+ 25 
N.S. 
 
69.6- 213.9 
128 + 16.4 
p< 0.05 
 
546 -1756 
1112 +86 
<0.001 
 
624-2116 
1233+153 
<0.001 
 
P* value, all groups vs control 
P** value, treated Vs untreated 
 
 
 
Figure 1: Serum aldose reductase activity in all studied groups (Mean SD). 
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Figure 2: Serum total antioxidant activity in all studied groups (Mean SD). 
 
 
GI G IIa GIIb GIIc GIId
TNF 32.33 163.21 86.7 91.3 75.7
IL-1 21.35 50.3 43.25 26.48 31.22
AGEs 26.2 152.7 100.3 83.4 76.5
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Figure 3: Serum (TNF- α), interleukine-1, and advanced glycated end products (AGEs) levels 
 
Serum glucose, HA1C levels in STZ-induced diabetic rats showed about four-fold elevation compared with control group 
(p<0.001). Treatment of diabetic rats with L-lutein, carnitine, combined were statistically significant (p<0.01,<0.001), 
(p<0.01,<0.01) ,(p<0.001,<0.001) respectively  decreased in the levels of glucose, HA1C compared with untreated diabetic.   
The combined effect was similar to metformin treatment. 
           The results in table (2) revealed that, a statistical significant elevation in the levels of saturated   palmitic acid, monounsaturated 
fatty acids ( palmitoleic oleic and arachidic) in diabetic rats.  
Treatment of diabetic rats with L-lutein or L-carnitine or combined   significantly reduction of saturated   palmitic acid (p<0.01), 
monounsaturated fatty acids (palmitoleic oleic and arachidic) (p<0.001). The effect of combined treatment nearly similar to metformin 
treatment. 
In diabetes rats, linoleic acid level was above normal, whereas arachidonic acid was below normal. However, diabetics rats 
treated with metformin arachidonic acids elevate significantly (p<0.05).  
              Administration of L-lutein, carnitine, combined to normal rats significantly decreased the levels of  myristic, palmitice, 
palmitoleic, stearic, linoleic, α-linolenic, arachidic and eicosadienoic when compared with control normal rats. Diabetic rats treated  
with L-lutein, L-carnitine, combined significantly (p<0.01) decreased the percentage of palmitic, stearic, oleic, arachidic compared with 
untreated rats.  
 
 
Discussion 
 
             Hyperglycemia plays an important role in the development and progression of diabetic complications [Kim et al., 2011]. The 
oxidative stress and AGEs can enhance inflammatory processes and diabetic complications [Trumbo  and  Ellwood,2006]. The 
elevation in serum glucose and HA1c levels in diabetic rats are in according to results obtained  [Alves-Rodrigues and  Shao 2004], 
who reported that, STZ-induced showed 4-5fold increase in the blood glucose levels after STZ administration.  
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            The hyperglycemia due to the toxic effects of STZ through glucose transporter-2, these lead to organ damage through activation of toxic 
accumulation of sorbitol in vital organs [Griffin et al.,1999].Treatment with lutein or carnitine and their combination significantly reduced elevated serum 
glucose This is in accordance to [Girard et al.,2005]. The combined effect is nearly similar to metformin action 
               These effects  of these supplements can be attributed to the antioxidant of lutein and combination with carnitine to reduce the glucose in the blood 
and stimulate the activity of pancreatic islets and insulin production in diabetic rats. The observations were consistent with the overall improvement of the 
complications associated with diabetes with insulin [Evans etal.,2001].Treatment with lutein combined with carnitine or with metformin were significantly 
lowered the levels of myristic, palmitic, palmitoleic and elevates the level of stearic acids when compared with the untreated dietiic rats.  
This is in accordance to results of [Gupta et al., 2013], who stated that, total saturated fatty acids were higher in the non-diabetic rats treated with lutein than 
untreated . Level of arachidonic may be decreased in diabetes and some degenerative diseases. Desaturase activities may be increased by insulin and diet 
restriction [Na  et al., 2011]. Insulin therapy can correct this defect by influencing the desaturase level. The results  obtained confirm that treatment with 
these supplements  have beneficial effects on the D-6 desaturase system and unsaturated fatty acid levels and  protective effects on unsaturated fatty acids 
and [Neyrinck et al.,       2013]. 
 
Conclusion 
 
It could be concluded that, abnormalities of fatty acids composition was observed in rats. It may be possible that, treatment with lutein alone or combined  
with L-carnitine could ameliorate toxicity induced by STZ and attenuate the changed fatty acid composition . 
 
 
 
Table 2: Fatty acids levels in different studied groups (Mean ± SD) 
  
 
Table (2); Fatty acids levels in different studied groups (Mean± SD). 
Animals groups 
 
Fatty acids 
Control 
group 
Diabetic Diabetic+ 
Lutein 
Diabetic 
+carnitine 
Diabetic+ 
lutein+ 
carnitine 
Diabetic+ 
metformin 
Myristic 14:0 0.99±0.04 1.1±0.24 1.0±0.11 1.0±0.12 1.0±0.21 1.1±0.20 
Palmitic 16:0 1.3±0.11 1.41±0.20 1.44±0.19 1.43±0.16 1.37±0.15 1.30±0.31 
Palmitoleic 16:1 0.45±0.12 0.49±0.09 0.48±0.07 0.43±0.05 0.40±0.1 0.40±0.08 
Stearic 18:0 2.7±0.63 2.88±0.83 2.93±0.93 2.81±0.73 2.99±0.89 2.62±0.63 
Oleic 18:1 1.3±0.06 1.56±0.09 1.65±0.11 1.77±0.12 1.52±0.32 1.81±0.41 
 α-Linolenic 18:3 1.89±0.09 1.49±0.29 1.55±0.39 1.61±0.41 1.71±0.53 1.91±0.32 
Linolenic 18:3 1.44±0.07 1.14±0.17 1.14±0.17 1.14±0.17 1.14±0.17 1.14±0.17 
Arachidic acid 20:0 0.92±0.05 1.3±0.35 1.1±0.25 1.2±0.33 1.0±0.41 0.94±0.44 
Ecosadienoic acid 20:2 0.98±0.55 1.2±0.65 1.3±0.45 1.1±0.35 1.4±0.71 1.2±0.56 
Mean values with different superscript letters in the same column are significantly different at p≤0.05 
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